Tamoxifen protects male mice nigrostriatal dopamine against methamphetamine-induced toxicity

Biochemical Pharmacology

Volumn 74, Issue 9, 2007, Pages 1413-1423

  Bourque, Mélanie ^a,b   Liu, Bin ^c   Dluzen, Dean E ^c   Di Paolo, Thérèse ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c Northeastern Ohio Medical University   (United States)

Author keywords

Dopamine; Neuroprotection; Parkinson's disease; Striatum; Substantia nigra

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; DOPAMINE TRANSPORTER; HOMOVANILLIC ACID; MESSENGER RNA; METHAMPHETAMINE; PREPROENKEPHALIN; TAMOXIFEN; VESICULAR MONOAMINE TRANSPORTER; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; DRUG EFFECT; IN SITU HYBRIDIZATION; MALE; MOUSE; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SUBSTANTIA NIGRA;

ANIMALS; BODY TEMPERATURE; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENKEPHALINS; MALE; METHAMPHETAMINE; MICE; MICE, INBRED STRAINS; NEUROTOXICITY SYNDROMES; PROTEIN PRECURSORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SUBSTANTIA NIGRA; TAMOXIFEN; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 34548834730     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.07.009     Document Type: Article

References (49)

1. Hornykiewicz O. Ageing and neurotoxins as causative factors in idiopathic Parkinson's disease-a critical analysis of the neurochemical evidence. Prog Neuropsychopharmacol Biol Psychiatry 13 (1989) 319-328
2. Shulman L.M., and Bhat V. Gender disparities in Parkinson's disease. Expert Rev Neurother 6 (2006) 407-416
3. Czlonkowska A., Ciesielska A., Gromadzka G., and Kurkowska-Jastrzebska I. Gender differences in neurological disease: role of estrogens and cytokines. Endocrine 29 (2006) 243-256
4. Davidson C., Gow A.J., Lee T.H., and Ellinwood E.H. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev 36 (2001) 1-22
5. Hanson G.R., Rau K.S., and Fleckenstein A.E. The methamphetamine experience: a NIDA partnership. Neuropharmacology 47 Suppl. 1 (2004) 92-100
6. Miller D.B., Ali S.F., O'Callaghan J.P., and Laws S.C. The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann NY Acad Sci 844 (1998) 153-165
7. Dluzen D.E., McDermott J.L., and Anderson L.I. Tamoxifen diminishes methamphetamine-induced striatal dopamine depletion in intact female and male mice. J Neuroendocrinol 13 (2001) 618-624
8. Dluzen D. Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine. Brain Res 767 (1997) 340-344
9. Callier S., Morissette M., Grandbois M., Pelaprat D., and Di Paolo T. Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice. Synapse 41 (2001) 131-138
10. D'Astous M., Gajjar T.M., Dluzen D.E., and Di Paolo T. Dopamine transporter as a marker of neuroprotection in methamphetamine-lesioned mice treated acutely with estradiol. Neuroendocrinology 79 (2004) 296-304
11. D'Astous M., Mickley K.R., Dluzen D.E., and Di Paolo T. Differential protective properties of estradiol and tamoxifen against methamphetamine-induced nigrostriatal dopaminergic toxicity in mice. Neuroendocrinology 82 (2005) 111-120
12. Dluzen D.E., Anderson L.I., and Pilati C.F. Methamphetamine-gonadal steroid hormonal interactions: effects upon acute toxicity and striatal dopamine concentrations. Neurotoxicol Teratol 24 (2002) 267-273
13. Gao X., and Dluzen D.E. The effect of testosterone upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Brain Res 892 (2001) 63-69
14. McDermott J.L., Anderson L.I., and Dluzen D.E. Tamoxifen alters dopamine output through direct actions upon superfused corpus striatal tissue fragments. Neurochem Int 32 (1998) 299-307
15. Dluzen D.E., and Mickley K.R. Gender differences in modulatory effects of tamoxifen upon the nigrostriatal dopaminergic system. Pharmacol Biochem Behav 80 (2005) 27-33
16. LaVoie M.J., and Hastings T.G. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J Neurosci 19 (1999) 1484-1491
17. Dluzen D.E., and McDermott J.L. Estrogen, anti-estrogen, and gender: differences in methamphetamine neurotoxicity. Ann NY Acad Sci 965 (2002) 136-156
18. Miller D.B., O'Callaghan J.P., and Ali S.F. Age as a susceptibility factor in the striatal dopaminergic neurotoxicity observed in the mouse following substituted amphetamine exposure. Ann NY Acad Sci 914 (2000) 194-207
19. Zhu J.P., Xu W., and Angulo J.A. Disparity in the temporal appearance of methamphetamine-induced apoptosis and depletion of dopamine terminal markers in the striatum of mice. Brain Res 1049 (2005) 171-181
20. Kitanaka N., Kitanaka J., and Takemura M. Behavioral sensitization and alteration in monoamine metabolism in mice after single versus repeated methamphetamine administration. Eur J Pharmacol 474 (2003) 63-70
21. Jourdain S., Morissette M., Morin N., and Di Paolo T. Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine mice. J Neuroendocrinol 17 (2005) 509-517
22. Franklin K., and Paxinos G. The mouse brain in stereotaxic coordinates (1997), Academic Press, San Diego
23. Kilbourn M., and Frey K. Striatal concentrations of vesicular monoamine transporters are identical in MPTP-sensitive (C57BL/6) and -insensitive (CD-1) mouse strains. Eur J Pharmacol 307 (1996) 227-232
24. D'Astous M., Morissette M., Callier S., and Di Paolo T. Regulation of striatal preproenkephalin mRNA levels in MPTP-lesioned mice treated with estradiol. J Neurosci Res 80 (2005) 138-144
25. Pasqualini C., Olivier V., Guibert B., Frain O., and Leviel V. Acute stimulatory effect of estradiol on striatal dopamine synthesis. J Neurochem 65 (1995) 1651-1657
26. Di Paolo T., Rouillard C., and Bedard P. 17Beta-estradiol at a physiological dose acutely increases dopamine turnover in rat brain. Eur J Pharmacol 117 (1985) 197-203
27. Chakravorty S.G., and Halbreich U. The influence of estrogen on monoamine oxidase activity. Psychopharmacol Bull 33 (1997) 229-233
28. Cappon G.D., Pu C., and Vorhees C.V. Time-course of methamphetamine-induced neurotoxicity in rat caudate-putamen after single-dose treatment. Brain Res 863 (2000) 106-111
29. Bustamante D., You Z.B., Castel M.N., Johansson S., Goiny M., Terenius L., et al. Effect of single and repeated methamphetamine treatment on neurotransmitter release in substantia nigra and neostriatum of the rat. J Neurochem 83 (2002) 645-654
30. Fumagalli F., Gainetdinov R.R., Valenzano K.J., and Caron M.G. Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. J Neurosci 18 (1998) 4861-4869
31. Adams D.H., Hanson G.R., and Keefe K.A. Cocaine and methamphetamine differentially affect opioid peptide mRNA expression in the striatum. J Neurochem 75 (2000) 2061-2070
32. Bezard E., Gross C.E., and Brotchie J.M. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci 26 (2003) 215-221
33. Zhu J.P., Xu W., and Angulo J.A. Distinct mechanisms mediating methamphetamine-induced neuronal apoptosis and dopamine terminal damage share the neuropeptide substance p in the striatum of mice. Ann NY Acad Sci 1074 (2006) 135-148
34. Kuo Y.M., Chen H.H., Shieh C.C., Chuang K.P., Cherng C.G., and Yu L. 4-Hydroxytamoxifen attenuates methamphetamine-induced nigrostriatal dopaminergic toxicity in intact and gonadetomized mice. J Neurochem 87 (2003) 1436-1443
35. McDonnell D.P. The molecular pharmacology of SERMs. Trends Endocrinol Metab 10 (1999) 301-311
36. Kuppers E., and Beyer C. Expression of estrogen receptor-alpha and beta mRNA in the developing and adult mouse striatum. Neurosci Lett 276 (1999) 95-98
37. Mitra S.W., Hoskin E., Yudkovitz J., Pear L., Wilkinson H.A., Hayashi S., et al. Immunolocalization of estrogen receptor beta in the mouse brain: comparison with estrogen receptor alpha. Endocrinology 144 (2003) 2055-2067
38. Smith C.L., and O'Malley B.W. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25 (2004) 45-71
39. Willett M.C., and Dluzen D.E. Tamoxifen increases methamphetamine-evoked dopamine output from superfused striatal tissue fragments of male mice. Brain Res 1029 (2004) 186-194
40. Dicko A., Morissette M., Ben Ameur S., Pezolet M., and Di Paolo T. Effect of estradiol and tamoxifen on brain membranes: investigation by infrared and fluorescence spectroscopy. Brain Res Bull 49 (1999) 401-405
41. Suuronen T., Nuutinen T., Huuskonen J., Ojala J., Thornell A., and Salminen A. Anti-inflammatory effect of selective estrogen receptor modulators (SERMs) in microglial cells. Inflamm Res 54 (2005) 194-203
42. Shy H., Malaiyandi L., and Timiras P.S. Protective action of 17beta-estradiol and tamoxifen on glutamate toxicity in glial cells. Int J Dev Neurosci 18 (2000) 289-297
43. Stephans S.E., and Yamamoto B.K. Methamphetamine-induced neurotoxicity: roles for glutamate and dopamine efflux. Synapse 17 (1994) 203-209
44. Abekawa T., Ohmori T., and Koyama T. Effects of repeated administration of a high dose of methamphetamine on dopamine and glutamate release in rat striatum and nucleus accumbens. Brain Res 643 (1994) 276-281
45. LaVoie M.J., Card J.P., and Hastings T.G. Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. Exp Neurol 187 (2004) 47-57
46. Thomas D.M., Walker P.D., Benjamins J.A., Geddes T.J., and Kuhn D.M. Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J Pharmacol Exp Ther 311 (2004) 1-7
47. Mandlekar S., and Kong A.N. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6 (2001) 469-477
48. Huff R.A., Vaughan R.A., Kuhar M.J., and Uhl G.R. Phorbol esters increase dopamine transporter phosphorylation and decrease transport Vmax. J Neurochem 68 (1997) 225-232
49. Vaughan R.A., Huff R.A., Uhl G.R., and Kuhar M.J. Protein kinase C-mediated phosphorylation and functional regulation of dopamine transporters in striatal synaptosomes. J Biol Chem 272 (1997) 15541-15546